Get the Stockscreener App
18.56
0.48%
-0.09
Fulgent Genetics Inc stock is traded at $18.56, with a volume of 140.47K.
It is down -0.48% in the last 24 hours and down -9.29% over the past month.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
See More
Previous Close:
$18.65
Open:
$18.63
24h Volume:
140.47K
Relative Volume:
0.39
Market Cap:
$510.68M
Revenue:
$320.35M
Net Income/Loss:
$-75.01M
P/E Ratio:
-7.7485
EPS:
-2.3953
Net Cash Flow:
$-113.17M
1W Performance:
-3.03%
1M Performance:
-9.29%
6M Performance:
-20.79%
1Y Performance:
-14.63%
1-Day Range:
$18.37
$18.68
1-Week Range:
$18.37
$19.34
52-Week Range:
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
18.56 | 514.81M | 320.35M | -75.01M | -113.17M | -2.3953 |
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Upgrade | UBS | Neutral → Buy |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript - AOL.com
Fulgent Genetics, Inc. $FLGT Shares Purchased by Quantinno Capital Management LP - MarketBeat
Fulgent Genetics (FLGT) Short Interest & Short Float | Updated Aug 2026 $FLGT - MarketBeat
Discipline and Rules-Based Execution in FLGT Response - Stock Traders Daily
Fulgent Genetics, Inc. $FLGT Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Wall Street Zen Downgrades Fulgent Genetics (NASDAQ:FLGT) to Strong Sell - MarketBeat
Fulgent Genetics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:FLGT) 2026-08-07 - Seeking Alpha
Price to sales forward of Fulgent Genetics, Inc. – MUN:7F0 - TradingView
Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating a Complicated Financial Landscape in Healthcare - directorstalkinterviews.com
Fulgent Genetics (FLGT) Stock Gets Fair Value Boost After Analysts Raised Targets - Yahoo Finance
Fulgent Deadline Alert - TMX Newsfile
FLGT Maintained by Piper Sandler -- Price Target Raised to $19.0 - GuruFocus
Piper Sandler Maintains Fulgent Genetics(FLGT.US) With Hold Rating, Cuts Target Price to $19 - Moomoo
Fulgent Genetics Inc (7F0) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Fulgent Genetics Latest Results: Cuts FY26 EPS Guidance to Loss - scanx.trade
Fulgent Genetics Inc (FLGT) (Q2 2026) Earnings Call Highlights: Strategic Progress Amid Revenue ... By GuruFocus - Investing.com Canada
Earnings call transcript: Fulgent Genetics cuts 2026 outlook after q2 miss - Investing.com Nigeria
FLGT Looks 16.7% Undervalued on GF Value™ Despite Revenue Miss - GuruFocus
Fulgent Genetics (FLGT) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. - marketscreener.com
Fulgent Reports Second Quarter 2026 Financial Results - Business Wire
Fulgent Genetics cuts FY26 revenue guidance amid billing delays - scanx.trade
Behavioral Patterns of FLGT and Institutional Flows - Stock Traders Daily
Fulgent Genetics CSO Gao Hanlin Executes Tax-Related Sale of 1,645 Shares at $19.67 on July 26, 2026 - Kalkine Media
Fulgent Genetics Inc (FLGT) Cash Flow - TradingKey
Fulgent Genetics Inc (FLGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fulgent Genetics Inc (FLGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fulgent Genetics Inc (FLGT) Institutional Confidence - TradingKey
FLGT|Fulgent Genetics Inc|Price:19.670|Chg%:-0.310 - TradingKey
Fulgent Genetics Slips 1.5% as Shares Test Key Support LevelsALMA Signal - dars.gov.et
TradingKey - TradingKey
FLGT|Fulgent Genetics Inc|Price:19.557|Chg%:-0.113 - TradingKey
Fulgent Genetics, Inc. Revenue Breakdown – FWB:7F0 - TradingView
FULGENT GENETICS, INC. (FLGT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulgent Genetics, Inc. (FLGT) - TMX Newsfile
Fulgent Genetics (FLGT.US) will release its earnings report after market close on July 30. - 富途牛牛
Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating Challenges with a -7.41% Potential Downside - DirectorsTalk Interviews
Fulgent Genetics Inc (FLGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fulgent Genetics (FLGT) to Release Earnings on Thursday - MarketBeat
(FLGT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ETFs Investing in Fulgent Genetics, Inc. Stocks - TradingView
Fulgent Genetics seen as undervalued with stron... - Pluang
Fulgent Genetics: Strong Moves By Management Keep Me Bullish (NASDAQ:FLGT) - Seeking Alpha
Y Intercept Hong Kong Ltd Invests $1.08 Million in Fulgent Genetics, Inc. $FLGT - MarketBeat
Fulgent Genetics Inc. (FLGT) Q1 2026 Earnings: EPS Misses Estimates as Losses Widen, Shares Edge Lower - dars.gov.et
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - Business Wire
Fulgent Genetics to announce Q2 2026 results on July 30 - scanx.trade
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting - AOL.com
FLGTFulgent Genetics Inc Forecast, Target Price - Finviz
Enterprise value to EBITDA forward of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Fulgent Genetics (FLGT) Dips 1%: Testing Key Support Near $19.3 Amid Mixed Technical SignalsVOLD Alert - dars.gov.et
Fulgent Genetics Inc Stock (FLGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):